Literature DB >> 15460090

A primary care approach to Sjögren's syndrome. Helping patients cope with sicca symptoms, extraglandular manifestations.

Chris T Derk1, Frederick B Vivino.   

Abstract

Sjögren's syndrome is a chronic, systemic, autoimmune inflammatory disorder characterized by lymphocytic infiltration of exocrine glands, most notably the salivary and lacrimal glands. It results in loss of functional epithelium, diminished exocrine function, and gradual onset of dryness of the eyes, mouth, and other body parts (sicca syndrome). Because most patients with Sjögren's syndrome are female, this syndrome also represents a major women's health problem that is often misdiagnosed and undertreated. In this article, Drs Derk and Vivino review the criteria for diagnosis, common signs and symptoms, and strategies for increasing patient comfort.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15460090     DOI: 10.3810/pgm.2004.09.1587

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

Review 1.  Toll-like receptors in ocular surface disease.

Authors:  Rachel L Redfern; Alison M McDermott
Journal:  Exp Eye Res       Date:  2010-03-24       Impact factor: 3.467

2.  Toll-like receptor expression and activation in mice with experimental dry eye.

Authors:  Rachel L Redfern; Nimesh Patel; Samuel Hanlon; William Farley; Margaret Gondo; Stephen C Pflugfelder; Alison M McDermott
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-28       Impact factor: 4.799

3.  Pilocarpine induces the residual secretion of salivary fluid in perfused submandibular glands of rats.

Authors:  Takanori Narita; Bing Qi; Masataka Murakami; Hiroshi Sugiya
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

4.  Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial.

Authors:  Cheng-Han Wu; Song-Chou Hsieh; Kuang-Lun Lee; Ko-Jen Li; Ming-Chi Lu; Chia-Li Yu
Journal:  J Formos Med Assoc       Date:  2006-10       Impact factor: 3.282

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.